Hikal Q2 FY25 revenue stood at Rs. 453 Cr
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The company uses iPS cells to develop treatments for diseases relating to the kidney
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Subscribe To Our Newsletter & Stay Updated